Agnoletto Chiara, Volinia Stefano
Rete Oncologica Veneta (ROV), Veneto Institute of Oncology IOV-IRCCS, Padua, Italy.
Laboratorio per le Tecnologie delle Terapie Avanzate (LTTA), Department of Translational Medicine, University of Ferrara, Ferrara, Italy.
Front Oncol. 2022 Aug 4;12:947479. doi: 10.3389/fonc.2022.947479. eCollection 2022.
Circulating tumor cells (CTCs) represent a subset of heterogeneous cells, which, once released from a tumor site, have the potential to give rise to metastasis in secondary sites. Recent research focused on the attempt to detect and characterize these rare cells in the circulation, and advancements in defining their molecular profile have been reported in diverse tumor species, with potential implications for clinical applications. Of note, metabolic alterations, involving mitochondria, have been implicated in the metastatic process, as key determinants in the transition of tumor cells to a mesenchymal or stemness-like phenotype, in drug resistance, and in induction of apoptosis. This review aimed to briefly analyse the most recent knowledge relative to mitochondria dysfunction in CTCs, and to envision implications of altered mitochondria in CTCs for a potential utility in clinics.
循环肿瘤细胞（CTCs）是异质性细胞的一个亚群，一旦从肿瘤部位释放，就有可能在继发部位引发转移。最近的研究集中在检测和表征循环中的这些稀有细胞，并且在多种肿瘤类型中都报道了在定义其分子特征方面取得的进展，这对临床应用具有潜在意义。值得注意的是，涉及线粒体的代谢改变与转移过程有关，是肿瘤细胞向间充质或干细胞样表型转变、耐药性以及诱导细胞凋亡的关键决定因素。本综述旨在简要分析关于CTCs中线粒体功能障碍的最新知识，并设想CTCs中线粒体改变在临床潜在应用中的意义。
